The group, 340B Health, sent a letter to the DOJ last Wednesday, saying Mylan’s alleged misclassification of EpiPens as a generic drug under the Medicaid Drug Rebate Program likely resulted in overcharges to 340B hospitals.
The 340B drug pricing program ensures hospitals treating a large proportion of low-income patients can buy drugs from manufacturers at a discount of 20 percent to 50 percent, according to The Washington Post.
“We’ve heard from our members that for each package of EpiPens that they’ve purchased, it appears they could have been overchanged by upwards [of] $500 per package,” Randy Barrett, spokesperson for 340B Health, told CNBC in an email. “One hospital reported to us that this would amount to an overcharge of more than $100,000 in the last year.”
Mr. Barrett was unable to provide an exact figure on how much money the safety-net hospitals may have been shorted.
More articles on supply chain:
Omnicell offers face-to-face expert support for hospital pharmacies
Diabetes drugmakers under federal scrutiny over potential price setting
Northern Arizona Healthcare Partners taps Premier for supply chain management
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.